France's industry minister Marc Ferracci stated that the government may block the deal between Sanofi and US private equity firm CD&R if commitments are not met. The deal involves a partial sale of Sanofi's consumer health subsidiary, Opella, which is known for its paracetamol product, Doliprane. Concerns have been raised about job security and medicine shortages. Political opposition spans across the spectrum, with calls for state intervention. French President Emmanuel Macron emphasized the importance of maintaining production in France despite foreign ownership.